Literature DB >> 1694680

HIV-1 reverse transcriptase purified from a recombinant strain of Escherichia coli.

P K Clark1, A L Ferris, D A Miller, A Hizi, K W Kim, S M Deringer-Boyer, M L Mellini, A D Clark, G F Arnold, W B Lebherz.   

Abstract

A better understanding of the structure and biochemical properties of the replicative machinery of human immunodeficiency virus type 1 (HIV-1) may be useful in the screening and design of drugs that could be used to treat AIDS. We have previously described a recombinant strain of Escherichia coli that produces HIV-1 reverse transcriptase (RT). Fermentation conditions for the large-scale growth of the bacterial strain and a protocol for the purification of an enzymatically active 66-Kd form of the RT have been developed. The purified RT has all of the appropriate enzymatic functions and properties. The recombinant protein can be substituted for the viral enzyme in structural and biochemical studies and used in screens for drugs that could inhibit HIV replication.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694680     DOI: 10.1089/aid.1990.6.753

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Distinct subsets of retroviruses encode dUTPase.

Authors:  J H Elder; D L Lerner; C S Hasselkus-Light; D J Fontenot; E Hunter; P A Luciw; R C Montelaro; T R Phillips
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

3.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution.

Authors:  A Jacobo-Molina; A D Clark; R L Williams; R G Nanni; P Clark; A L Ferris; S H Hughes; E Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases.

Authors:  S Loya; A Rudi; Y Kashman; A Hizi
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

6.  Mode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerases.

Authors:  S Loya; A Rudi; Y Kashman; A Hizi
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

7.  Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

8.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.

Authors:  Devrishi Goswami; Steve Tuske; Bruce D Pascal; Joseph D Bauman; Disha Patel; Eddy Arnold; Patrick R Griffin
Journal:  Anal Chem       Date:  2015-03-25       Impact factor: 6.986

10.  Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine.

Authors:  W S Marshall; G Beaton; C A Stein; M Matsukura; M H Caruthers
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.